Contributor Disclosures for Posterior Cerebral Artery Stroke

Role Name Disclosure Details Author  Michael D Hill, MD, Medical Director, Stroke Unit, Assistant Professor of Neurology, Department of Clinical Neurosciences, Foothills Hospital, University of Calgary, Canada Hoffmann La Roche Canada Ltd Details Coauthor  Alastair M Buchan, MBBCh, FCCPC, Professor, Department of Clinical Neurosciences, Foothills Hospital, University of Calgary, Canada Nothing to disclose Details Medical Editor  Thomas A Kent, MD, Professor, Department of Neurology, Baylor College of Medicine; Neurology Care Line Executive, Michael E DeBakey Veterans Affairs Medical Center Nothing to disclose Details Pharmacy Editor  Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine Nothing to disclose Details Managing Editor  Howard S Kirshner, MD, Professor of Neurology, Psychiatry and Hearing and Speech Sciences, Vice Chairman, Department of Neurology, Vanderbilt University School of Medicine; Director, Vanderbilt Stroke Center; Program Director, Stroke Service, Vanderbilt Stallworth Rehabilitation Hospital; Consulting Staff, Department of Neurology, Nashville Veterans Affairs Medical Center Boehringer Ingelheim BMS/Sanofi Pfizer Novartis Details CME Editor  Matthew J Baker, MD, Consulting Staff, Collier Neurologic Specialists, Naples Community Hospital Nothing to disclose Details Chief Editor  Helmi L Lutsep, MD, Associate Professor, Department of Neurology, Oregon Health and Science University; Associate Director, Oregon Stroke Center Co-Axia Talecris AGA Medical Boehringer Ingelheim Boston Scientific Details CONTRIBUTOR DISCLOSURE FORM Contributor Name: Michael D Hill  DECLARATION STATEMENT I and/or my spouse/partner have no financial interest with any organization that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity. I and/or my spouse/partner have a financial interest/arrangement with one or more organization(s), including but not limited to the organization(s) supporting this activity, that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity. COMMERCIAL INTEREST (Name of Organization) Self Spouse/ Partner NATURE OF RELEVANT FINANCIAL RELATIONSHIP What was received?* For what role?** Hoffmann La Roche Canada Ltd Honoraria Speaking and teaching   Off label or investigational use of medication Contributor Disclosure Contributor: Contributor Disclosure: Alastair M Buchan, Coauthor  The contributor discloses no conflict of interest.  CONTRIBUTOR DISCLOSURE FORM Contributor Name: Thomas A Kent  DECLARATION STATEMENT I and/or my spouse/partner have no financial interest with any organization that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity. I and/or my spouse/partner have a financial interest/arrangement with one or more organization(s), including but not limited to the organization(s) supporting this activity, that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity. COMMERCIAL INTEREST (Name of Organization) Self Spouse/ Partner NATURE OF RELEVANT FINANCIAL RELATIONSHIP What was received?* For what role?** Off label or investigational use of medication CONTRIBUTOR DISCLOSURE FORM Contributor Name: Francisco Talavera  DECLARATION STATEMENT I and/or my spouse/partner have no financial interest with any organization that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity. I and/or my spouse/partner have a financial interest/arrangement with one or more organization(s), including but not limited to the organization(s) supporting this activity, that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity. COMMERCIAL INTEREST (Name of Organization) Self Spouse/ Partner NATURE OF RELEVANT FINANCIAL RELATIONSHIP What was received?* For what role?** Off label or investigational use of medication CONTRIBUTOR DISCLOSURE FORM Contributor Name: Howard S Kirshner  DECLARATION STATEMENT I and/or my spouse/partner have no financial interest with any organization that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity. I and/or my spouse/partner have a financial interest/arrangement with one or more organization(s), including but not limited to the organization(s) supporting this activity, that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity. COMMERCIAL INTEREST (Name of Organization) Self Spouse/ Partner NATURE OF RELEVANT FINANCIAL RELATIONSHIP What was received?* For what role?** Boehringer Ingelheim Honoraria Speaking and teaching   BMS/Sanofi Honoraria Speaking and teaching   Pfizer Honoraria Speaking and teaching   Novartis Consulting fee Review panel membership   Off label or investigational use of medication Contributor Disclosure Contributor: Contributor Disclosure: Matthew J Baker, CME Editor  The contributor discloses no conflict of interest.  CONTRIBUTOR DISCLOSURE FORM Contributor Name: Helmi L Lutsep  DECLARATION STATEMENT I and/or my spouse/partner have no financial interest with any organization that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity. I and/or my spouse/partner have a financial interest/arrangement with one or more organization(s), including but not limited to the organization(s) supporting this activity, that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity. COMMERCIAL INTEREST (Name of Organization) Self Spouse/ Partner NATURE OF RELEVANT FINANCIAL RELATIONSHIP What was received?* For what role?** Co-Axia Consulting fee Review panel membership   Talecris Consulting fee Review panel membership   AGA Medical Consulting fee Review panel membership   Boehringer Ingelheim Honoraria Speaking and teaching   Boston Scientific Honoraria Speaking and teaching   Off label or investigational use of medication As part of clinical trials that are reviewed by the IRB